Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

J Beck (NPI 1952372120)

Field	Value
Entity Type	Individual
Organization	J Beck
Address	3901 Parkway Cir Ste 100
City	Springdale
State	AR
ZIP	72762
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 27, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider’s revenue is effectively single‑payer: Total Medicare revenue is $2.2M and there is no Medicaid billing on file, indicating the practice’s Medicare activity accounts for its entire recorded public‑payer footprint. Absence of Medicaid billing on file suggests the dataset reflects a Medicare‑centric patient mix rather than a dual‑payer practice profile.

Revenue is highly concentrated in a small set of infused biologics: the top three Medicare codes account for 63.6% of the provider’s total Medicare revenue. Those top contributors are J9271 $653.6K (31.3% of Medicare revenue), J9144 $403.6K (19.3%), and J1561 $270.6K (13.0%), underscoring dependence on a narrow set of high‑revenue drug administrations.

Clinical and service‑line mix points to an infusion‑based hematology/oncology practice: large volumes of J9271 (pembrolizumab), J9144 (daratumumab) and J9299 (nivolumab) combined with chemotherapy administration codes such as 96413 (506 claims, $44K revenue) and 96365 (272 claims, $12K revenue) indicate routine outpatient infusion of oncologic biologics and cytotoxics. Diagnostic support for cancer care is present as well — 78815 PET/CT (123 claims, $123.6K revenue) and CT abdomen/pelvis 74178 (118 claims, $20.4K) appear among top billings.

Competitive standing on the key drug codes is modest-to-moderate nationally: J9271 ranks #671 of 1841 providers nationally (63th percentile; typical, unremarkable volume), J9144 ranks #185 of 615 (69th percentile; typical, unremarkable volume), and J1561 ranks #47 of 180 (74th percentile; typical, unremarkable volume). These ranks suggest the provider is not a national outlier for pembrolizumab or daratumumab use but has relatively stronger placement for immune globulin (J1561) compared with peers.

Several non‑drug services show unusually high relative volume, signaling active outpatient management and diagnostics: 99214 (826 claims, $70.2K revenue) ranks in the 96th percentile and is labeled notably above typical national volume, and CT abdomen/pelvis 74178 also sits in the 96th percentile (118 claims, $20.4K). High percentile placement for E/M and imaging implies substantial ongoing follow‑up and diagnostic work for a Medicare patient population.

Laboratory and routine infusion support are significant operational drivers: 80053 (1.7K claims, $16.7K revenue) and 85025 (1.9K claims, $15.4K revenue) both rank at the 97th percentile, indicating heavy use of lab panels and CBCs to support active oncology care. Multiple administration add‑ons and follow‑on infusion codes (96367, 96401, 96417) also appear in the top‑25, reinforcing an infusion‑centric workflow.

The top biologics combine very high claim counts with relatively modest average paid per claim, which points to revenue being driven by volume of billed units rather than large per‑claim payments: J9271 shows 15.2K claims with $43 avg paid/claim, J9144 shows 10.6K claims with $38 avg paid/claim, and J1561 shows 7.1K claims with $38 avg paid/claim. This pattern is consistent with high‑frequency unit billing for oncology biologics and supportive agents rather than a few very large single‑claim payments.

Provider tenure is long: the NPI was enumerated on 2006-01-27 (~20 years ago), indicating an established practice. Combined with the Medicare‑only billing record and stable patterns of infusion, imaging, and lab utilization, the data depict a long‑standing hematology/oncology clinician operating an outpatient infusion and diagnostic service focused on Medicare beneficiaries.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

103 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,200	$40	$653.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,620	$40	$403.6K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	7,120	$40	$270.6K
J9299	Injection, nivolumab, 1 mg	7,840	$20	$188.2K
J0897	Injection, denosumab, 1 mg	7,500	$20	$135K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	120	$1,010	$123.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	830	$90	$70.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	510	$90	$44K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	170	$130	$21.8K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	130	$160	$20.9K

Showing 1–10 of 103

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 103 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

J Beck — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

103 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	30	40	20,700	$40	$896.3K
J9299	27	30	15,660	$20	$432.9K
J9144	6	10	10,530	$40	$361.9K
J1561	4	10	5,930	$40	$216.4K
J0897	31	160	2,580	$20	$89.7K
78815	43	100	90	$550	$83.7K
J0885	30	40	4,070	$10	$38K
96413	31	80	380	$90	$36.6K
A9552	23	40	180	$150	$28.9K
J9217	42	50	100	$130	$20K

Showing 1–10 of 103

Related Providers

Other providers that share a Tax Identification Number (TIN) with J Beck, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
Stephan Rosenfeld	AR	Hematology & Oncology Physician	$2.3M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0
Mitchell Ross	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as J Beck, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ozark Guidance Center, Inc	AR	Community/Behavioral Health Agency	$0	$74.5M
Arkansas Childrens Northwest, Inc.	AR	Children's Hospital	$0	$48M
Arisa Health, Inc.	AR	Community/Behavioral Health Agency	$0	$14.9M
Jarvis Pediatric Therapy, Inc.	AR	Specialist	$0	$10.6M
Wendy Cassady Speech Pathology, Inc	AR	Speech-Language Pathologist	$0	$9.2M
Preferred Family Healthcare Inc	AR	Community/Behavioral Health Agency	$0	$8.1M
Kidscorp Of Fayetteville, Inc	AR	Developmental Disabilities Clinic/Center	$0	$6.9M
University Of Arkansas For Medical Sciences	AR	Developmental - Behavioral Pediatrics Physician	$0	$5.8M
Northwest Physicians LLC	AR	Obstetrics Physician	$0	$5.8M
All Aboard Pediatric Therapy	AR	Pediatric Occupational Therapist	$0	$5.3M

J Beck — Billing Profile & Reimbursement Data

Sign up for J Beck — Billing Profile & Reimbursement Data policy alerts

J Beck — Billing Profile & Reimbursement Data

Sign up for J Beck — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References